首页 | 本学科首页   官方微博 | 高级检索  
     


Control of mTORC1 signaling by the Opitz syndrome protein MID1
Authors:Liu Enbo  Knutzen Christine A  Krauss Sybille  Schweiger Susann  Chiang Gary G
Affiliation:aSignal Transduction Program, Sanford-Burnham Medical Research Institute, La Jolla, CA 92037;;bMax-Planck-Institute for Molecular Genetics, 14195 Berlin, Germany;;cDZNE (German Center for Neurodegenerative Disorders), 53127 Bonn, Germany; and;dDivision of Medical Sciences, University of Dundee Medical School, Dundee DD1 9SY, United Kingdom
Abstract:Mutations in the MID1 gene are causally linked to X-linked Opitz BBB/G syndrome (OS), a congenital disorder that primarily affects the formation of diverse ventral midline structures. The MID1 protein has been shown to function as an E3 ligase targeting the catalytic subunit of protein phosphatase 2A (PP2A-C) for ubiquitin-mediated degradation. However, the molecular pathways downstream of the MID1/PP2A axis that are dysregulated in OS and that translate dysfunctional MID1 and elevated levels of PP2A-C into the OS phenotype are poorly understood. Here, we show that perturbations in MID1/PP2A affect mTORC1 signaling. Increased PP2A levels, resulting from proteasome inhibition or depletion of MID1, lead to disruption of the mTOR/Raptor complex and down-regulated mTORC1 signaling. Congruously, cells derived from OS patients that carry MID1 mutations exhibit decreased mTORC1 formation, S6K1 phosphorylation, cell size, and cap-dependent translation, all of which is rescued by expression of wild-type MID1 or an activated mTOR allele. Our findings define mTORC1 signaling as a downstream pathway regulated by the MID1/PP2A axis, suggesting that mTORC1 plays a key role in OS pathogenesis.
Keywords:ubiquitin ligase   proteasome-mediated degradation
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号